Serina Therapeutics Inc (SER) Stock Price, Quote & News

Company Profile

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214 a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which...

Industry: Biotechnology

Sector: Healthcare

Phone: 256 327 9630

Website: serinatherapeutics.com

Address:

601 Genome Way, Suite 2001, Huntsville, United States

focafoca99 Apr. 7 at 9:08 PM

$SER is promoting a summit presentation on POZ-based lipid nanoparticles and ionizable lipids.

0 · Reply

Eliza1 Apr. 7 at 4:13 PM

$SER a PR after the presentation would give this stock a boost. Obviously, they have something positive to say.

1 · Reply

Eliza1 Apr. 7 at 1:28 PM

$SER https://finance.yahoo.com/sectors/healthcare/articles/serina-therapeutics-present-5th-lnp-100000383.html

0 · Reply

focafoca99 Apr. 3 at 8:30 PM

$SER says NYSE American accepted its compliance plan, which removes the immediate listing overhang but leaves execution to prove out.

0 · Reply

Eliza1 Apr. 2 at 11:41 PM

$SWMR $EVTV $SER all could go much higher Monday.

0 · Reply

Eliza1 Apr. 2 at 9:16 PM

$SER hmmm , perhaps with this news this stock can head up to 4 or 5 on Monday.

0 · Reply

gamgee11 Apr. 2 at 8:17 PM

$SER nice green

0 · Reply

Eliza1 Apr. 1 at 11:57 PM

$SER like $CYCN, OPEN AT $4 +

0 · Reply

Eliza1 Mar. 31 at 6:16 PM

$EVTV $COMP IS UP 3%! the small caps will follow-trade accordingly which means cover your shorts now-$SER $SWMR are all included at the very least.

0 · Reply

Eliza1 Mar. 31 at 5:22 PM

$SER $5 here we come

0 · Reply

Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit

Apr 2, 2026, 4:13 PM EDT - 5 days ago

Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan

Mar 24, 2026, 6:00 AM EDT - 14 days ago

Serina Therapeutics to Present at the 38th Annual Roth Conference

Mar 18, 2026, 4:10 PM EDT - 20 days ago

Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson's Disease

Feb 24, 2026, 4:05 PM EST - 6 weeks ago

Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

Feb 19, 2026, 6:00 AM EST - 6 weeks ago

Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

Feb 3, 2026, 6:00 AM EST - 2 months ago

Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event

Jan 28, 2026, 4:12 PM EST - 2 months ago

Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson's disease

Jan 15, 2026, 4:30 PM EST - 2 months ago

Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity

Dec 11, 2025, 4:15 PM EST - 4 months ago

Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry

Dec 10, 2025, 4:30 PM EST - 4 months ago

Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program

Nov 13, 2025, 6:10 AM EST - 5 months ago

Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Nov 3, 2025, 6:05 AM EST - 5 months ago

Serina Therapeutics Provides Regulatory Update on SER-252 Program

Oct 8, 2025, 11:00 AM EDT - 6 months ago

Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors

Oct 6, 2025, 4:15 PM EDT - 6 months ago

Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson's Disease

Sep 9, 2025, 3:20 PM EDT - 7 months ago

Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson's Disease

Sep 8, 2025, 6:00 AM EDT - 7 months ago

Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 25, 2025, 4:15 PM EDT - 8 months ago

Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson's Disease under 505(b)(2) NDA Pathway

Aug 11, 2025, 4:30 PM EDT - 8 months ago

Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Jul 29, 2025, 6:44 AM EDT - 9 months ago

Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)

Jul 28, 2025, 6:00 AM EDT - 9 months ago

Serina Therapeutics to Present at the BTIG Virtual Biotechnology Conference

Jul 10, 2025, 4:10 PM EDT - 9 months ago

Serina Therapeutics Makes Grant to New Employee Under Inducement Plan

Jul 1, 2025, 4:15 PM EDT - 10 months ago

Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting

Jun 23, 2025, 7:24 PM EDT - 10 months ago

Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025

Jun 17, 2025, 8:30 PM EDT - 10 months ago

UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42

Jun 17, 2025, 6:00 AM EDT - 10 months ago

Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42

Jun 9, 2025, 4:05 PM EDT - 10 months ago

Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?"

May 22, 2025, 4:50 PM EDT - 11 months ago

Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors

May 14, 2025, 3:15 PM EDT - 11 months ago

Serina Therapeutics Makes Grants to New Employees Under Inducement Plan

May 8, 2025, 4:23 PM EDT - 11 months ago

Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

Apr 29, 2025, 6:00 AM EDT - 1 year ago

Serina Therapeutics to Present at JonesResearch Virtual CNS Day

Apr 15, 2025, 6:30 AM EDT - 1 year ago

Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit

Apr 8, 2025, 4:30 PM EDT - 1 year ago

Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease

Apr 7, 2025, 6:30 AM EDT - 1 year ago

Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference

Mar 24, 2025, 4:30 PM EDT - 1 year ago

Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Mar 24, 2025, 6:30 AM EDT - 1 year ago

Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting

Feb 12, 2025, 4:15 PM EST - 1 year ago

Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors

Feb 3, 2025, 4:30 PM EST - 1 year ago

Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

Jan 15, 2025, 4:05 PM EST - 1 year ago

Serina Therapeutics Announces Sale of UniverXome Subsidiary

Jan 14, 2025, 5:25 PM EST - 1 year ago

Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors

Dec 16, 2024, 6:00 AM EST - 1 year ago

Serina Therapeutics to Present at Tribe Public's Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024

Dec 11, 2024, 6:05 AM EST - 1 year ago

Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit

Dec 2, 2024, 5:22 PM EST - 1 year ago

Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

Nov 12, 2024, 5:00 PM EST - 1 year ago

Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Sep 4, 2024, 6:42 PM EDT - 1 year ago

Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 9, 2024, 4:15 PM EDT - 1 year ago

Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Jul 29, 2024, 8:30 AM EDT - 1 year ago

Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit

Jul 18, 2024, 5:00 PM EDT - 1 year ago

Serina Therapeutics Appoints Srini Tenjarla, Ph.D. as Senior Vice President of CMC and Formulation

May 14, 2024, 4:05 PM EDT - 2 years ago

Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights

Apr 17, 2024, 4:05 PM EDT - 2 years ago

Serina Therapeutics Appoints Dr. Simba Gill as Executive Chairman

focafoca99 Apr. 7 at 9:08 PM

$SER is promoting a summit presentation on POZ-based lipid nanoparticles and ionizable lipids.

0 · Reply

Eliza1 Apr. 7 at 4:13 PM

$SER a PR after the presentation would give this stock a boost. Obviously, they have something positive to say.

1 · Reply

Eliza1 Apr. 7 at 1:28 PM

$SER https://finance.yahoo.com/sectors/healthcare/articles/serina-therapeutics-present-5th-lnp-100000383.html

0 · Reply

focafoca99 Apr. 3 at 8:30 PM

$SER says NYSE American accepted its compliance plan, which removes the immediate listing overhang but leaves execution to prove out.

0 · Reply

Eliza1 Apr. 2 at 11:41 PM

$SWMR $EVTV $SER all could go much higher Monday.

0 · Reply

Eliza1 Apr. 2 at 9:16 PM

$SER hmmm , perhaps with this news this stock can head up to 4 or 5 on Monday.

0 · Reply

gamgee11 Apr. 2 at 8:17 PM

$SER nice green

0 · Reply

Eliza1 Apr. 1 at 11:57 PM

$SER like $CYCN, OPEN AT $4 +

0 · Reply

Eliza1 Mar. 31 at 6:16 PM

$EVTV $COMP IS UP 3%! the small caps will follow-trade accordingly which means cover your shorts now-$SER $SWMR are all included at the very least.

0 · Reply

Eliza1 Mar. 31 at 5:22 PM

$SER $5 here we come

0 · Reply

Eliza1 Mar. 31 at 5:20 PM

$SER forget $COMP-LOOK at $QQQ ,

0 · Reply

Eliza1 Mar. 31 at 5:14 PM

$SER OMG look at $COMP- now I am very bullish and the small caps will catch up and then some!!

0 · Reply

Stock_Catcher Mar. 31 at 1:35 PM

$BFRG and $SER mentioned earlier Multi Day Angle , Great Moves

2 · Reply

Stock_Catcher Mar. 31 at 12:57 PM

$SER Multi Day

0 · Reply

Eliza1 Mar. 30 at 11:08 PM

$SER once again, do not buy this stock.

2 · Reply

Eliza1 Mar. 30 at 10:53 PM

$SER sell now

1 · Reply

JonSn0w Mar. 30 at 10:33 PM

$SER

1 · Reply

Eliza1 Mar. 30 at 8:48 PM

$SER someone is filling the upside gaps-if you are shorting-that is a positive! go with the trend.

0 · Reply

Eliza1 Mar. 30 at 7:16 PM

$SER As I said-keep on shorting!! also-watch $UGRO and $SWMR- they can move quickly , but watch the stats to go long or short

0 · Reply

Eliza1 Mar. 30 at 6:42 PM

$SER I am short now and made back my loss from being long-my apologies to anyone that bought on my bullish sentiment. I am staying short until it falls under a $1 Caution to the wind after that-do not buy the Shorts or the MMs shorts-let them play with each other

1 · Reply

RowanG Mar. 30 at 5:54 PM

$SER is the stock I was talking about.

0 · Reply

Eliza1 Mar. 30 at 5:42 PM

$SER I agree, none of them are buys here.

0 · Reply

Market Cap	26.48M
Revenue (ttm)	130,000.00
Net Income (ttm)	-19.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-14,753.85%
Debt to Equity Ratio	1.82

Volume	132,927
Avg Vol	5,608,578
Day's Range	N/A - N/A
Shares Out	12.31M
Stochastic %K	23%
Beta	1.21
Analysts	Strong Sell
Price Target	$13.00